Zager, J. S., Orloff, M. M., Ferrucci, P. F., Glazer, E. S., Ejaz, A., Richtig, E., … Ottensmeier, C. (2022). FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Zager, Jonathan S., Marlana M. Orloff, Pier Francesco Ferrucci, Evan Scott Glazer, Aslam Ejaz, Erika Richtig, Sebastian Ochsenreither, et al. “FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Zager JS, Orloff MM, Ferrucci PF, Glazer ES, Ejaz A, Richtig E, et al. FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Zager, Jonathan S., et al. “FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Zager JS, Orloff MM, Ferrucci PF, Glazer ES, Ejaz A, Richtig E, Ochsenreither S, Lowe MC, Reddy SA, Beasley G, Gesierich A, Dummer R, Arance AM, Fenwick SW, Wheater M, Ottensmeier C. FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). JOURNAL OF CLINICAL ONCOLOGY. 2022.